Cipla, with its leadership in inhalation, focus on green chemistry and potential deployment of cash savings for new growth drivers, warrants attention

Buy Cipla; target of Rs 940: Dolat Capital Market

Dolat Capital Market is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 940 in its research report dated May 15, 2021.

Cipla — While COVID scope continues, watch out for FY23

Just when it seemed that Covid tailwinds are waning for Cipla, the drug maker has repositioned itself for the opportunities emerging from the second wave of the pandemic

Buy Cipla: target of Rs 1100: Sharekhan

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated April 16, 2021.

Solara Active: Aurore deal to act as a booster for CRAMS; accumulate

The Aurore deal should help Solara in ramping up CRAMS portfolio, diversifying the API product basket and also aiding backward integration

Buy Cipla; target of Rs 940: Dolat Capital Market

Dolat Capital Market is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 940 in its research report dated January 31, 2021.

Cadila: COVID vaccine to be the key differentiator in the near term

In the next fiscal, Cadila plans to launch 40-plus products, including 8-10 complex molecules which should offset pricing erosion

Buy Cipla; target of Rs 950: Sharekhan

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 950 in its research report dated January 29, 2021.

Accumulate Cipla; target of Rs 913: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Cipla with a target price of Rs 913 in its research report dated February 01, 2021.

Buy Cipla; target of Rs 975: ICICI Direct

ICICI Direct is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 975 in its research report dated January 30, 2021.

Neutral Cipla; target of Rs 900: Motilal Oswal

Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 900 in its research report dated January 30, 2021.

Buy Cipla; target of Rs 1020: HDFC Securities

HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1020 in its research report dated February 01, 2021.

Cipla — Large part of COVID opportunity has played out

In the US market, Albuterol opportunity remains a key lever for Cipla at least till the time Perrigo re-enters although in terms of market share, the drugmaker may be close to maturity

Buy Cipla; target of Rs 940: HDFC Securities

HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 940 in its research report dated December 14, 2020.

Buy Cipla; target of Rs 887: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 887 in its research report dated December 14, 2020.

Hold Cipla; target of Rs 836: Prabhudas Lilladher

Prabhudas Lilladher recommended Hold rating on Cipla with a target price of Rs 836 in its research report dated November 09, 2020.

Buy Cipla: target of Rs 950: Sharekhan

Sharekhan is bullish on Cipla recommended buy rating on the stock with a target price of Rs 950 in its research report dated November 06, 2020.

Buy Cipla; target of Rs 942: Dolat Capital Market

Dolat Capital Market is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 942 in its research report dated November 07, 2020.

Buy Cipla; target of Rs 925: ICICI Direct

ICICI Direct is bullish on Cipla recommended buy rating on the stock with a target price of Rs 925 in its research report dated November 07, 2020.

Cipla: Covid opportunity and traction for Albuterol strong positives; accumulate

Cipla continues to be a significant pharma play during the pandemic because of its strong respiratory and a growing Covid portfolio

Reduce Cipla; target of Rs 657: Prabhudas Lilladher

Prabhudas Lilladher recommended Reduce rating on Cipla with a target price of Rs 657 in its research report dated October 13, 2020.

Cadila: a formidable play in Covid times and beyond

Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.

Buy Cipla; target of Rs 894 KRChoksey

KRChoksey is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 894 in its research report dated August 12, 2020.

Neutral Cipla; target of Rs 790: Motilal Oswal

Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 790 in its research report dated August 08, 2020.

Buy Cipla; target of Rs 805: HDFC Securities

HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 805 in its research report dated August 10, 2020.